Our TIDE analysis showed that a low expression of IGF2BP3 was associated with good immunotherapy response; this is similar to the predictive value of PD-L1, which regulates the tumor immune microenvironment through Th2/CD4+ effector memory T-cell imbalance, while PD-L1 suppresses the immune response through direct interaction with T-cell receptors. The gene discussed is IGF2BP3; the disease is neoplasm.